Yearly Archives: 2018

Cambium Enrolls First Patient in Phase I/II Study to Evaluate Platelet Lysate Biologic for Graft-vs.-Host Disease Dry Eye

ATLANTA, GA – June 15, 2018 – Cambium Medical Technologies (“Cambium”), a clinical stage company, announced today first patient enrollment for its Elate Ocular® topical fibrinogen-depleted human platelet lysate biologic in a randomized, multicenter, double-masked placebo-controlled parallel Phase I/II study. The study is designed to determine safety and exploratory efficacy in patients with dry eye ...
Read more